Phase 3 Schizophrenia Trial, Recruiting NCT06191965 Sponsor: Mclean Hospital Condition: Schizophrenia
Back to Schizophrenia

Phase 3 Schizophrenia Trial, Recruiting

NCT06191965
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 35 years old (male or female)
  • You have been diagnosed with schizophreniform disorder, schizophrenia, schizoaffective disorder, or unspecified psychosis
  • You have been receiving treatment for psychosis for less than five years
  • Your symptoms are below a certain level of severity, as measured by a standard rating scale called the PANSS (confirm with trial site)
  • You are able to understand and agree to take part in the study on your own

Who may not be able to join:

  • You have been diagnosed with a substance use disorder (such as alcohol or drug addiction) in the past 6 months — note that tobacco use and mild-to-moderate cannabis use do not disqualify you
  • You have an active medical condition that currently requires changes to your treatment, such as an autoimmune disease, active infection, HIV/AIDS, cancer, kidney failure, liver problems, heart disease, or an abnormal thyroid — however, stable, well-managed chronic conditions are generally acceptable
  • You have epilepsy or another condition that causes seizures
  • You have an intellectual disability or a history of significantly low IQ
  • You are under legal guardianship
  • You do not speak English, as the study tools have only been developed and tested in English
  • You have a known allergy to MitoQ (the supplement being studied in this trial)
  • You have taken antioxidant supplements — such as fish oil, Vitamin E, Vitamin C, multivitamins, or NAC — within the last 14 days (confirm with trial site, as stopping these may make you eligible)
  • You are under 18, pregnant, planning to become pregnant during the study, or currently breastfeeding
  • You are a woman who could become pregnant and are not willing or able to use a reliable form of contraception throughout the study (confirm with trial site for what counts as acceptable contraception)
  • You are a member of the study staff, a family member of study staff, or someone who depends on a staff member

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dost Ongur, MD, PhD, Mclean Hospital

Phone: 6178553922

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Mclean Hospital
Registry
ClinicalTrials.gov
Start date
1 June 2024
Est. completion
31 January 2027

Where this trial is recruiting

🇨🇭 Switzerland 🇺🇸 United States

Primary endpoints

Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) composite score at week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov